Holen Sie sich die Stockscreener-App
8.70
3.12%
-0.35
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals (CRBP) Gains FDA Nod for Pivotal CRB-701 - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. initiates FDA-cleared registrational study for CRB-701 in oropharyngeal cancer - Traders Union
FDA clears Corbus registrational trial for head and neck cancer drug - Investing.com Canada
Corbus Pharmaceuticals Announces FDA Clearance to Initiate - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BlackRock, Inc. (CRBP) discloses 5.9% beneficial ownership in Corbus Pharmaceuticals - Stock Titan
Form 144 Corbus Pharmaceuticals Holdings For: 27 July By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CRBP|Corbus Pharmaceuticals Holdings Inc|Price:9.170|Chg%:-0.150 - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Cash Flow - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corbus Pharmaceuticals Market Sentiment - Benzinga España
TradingKey - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Institutional Confidence - TradingKey
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc (CRBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals stock steadies as pipeline advances after equity raise - Ad-hoc-news.de
Corbus Pharmaceuticals Holdings Inc. Stock Climbs 5.4%, Outperforms Peers - Bitget
(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesHigh Growth Earnings - dars.gov.et
Corbus Pharmaceuticals (CRBP) Q1 2026 Earnings: Narrower-than-Expected Loss but Stock DeclinesEarnings Quality Analysis - dars.gov.et
Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals (CRBP) Surges 4.22% as Shares Test Key ResistanceOvervalued Signals - dars.gov.et
Corbus Pharmaceuticals appoints Leonardo Viana Nicacio as chief medical officer - MSN
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer - citybiz
Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer - marketscreener.com
Corbus Pharmaceuticals names Leonardo Nicacio as CMO By Investing.com - Investing.com South Africa
Leonardo Viana Nicacio appointed as chief medical officer at Corbus Pharmaceuticals Holdings, Inc. - Traders Union
Corbus Pharmaceuticals Appoints CMO Amid Key Trial Launches - TipRanks
Corbus Pharmaceuticals names Leonardo Nicacio as CMO - Investing.com
Corbus Pharmaceuticals (NASDAQ: CRBP) hires new CMO and details CRB-701, CRB-913 timelines - Stock Titan
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer - The Manila Times
Corbus Pharmaceuticals outlines its immuno-oncology strategy as a clinical-stage biotech - Ad-hoc-news.de
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
CRBP issuer: affiliate Dominic Smethurst plans resale of 23,025 shares (CRBP) - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
(CRBP) Risk Channels and Responsive Allocation - Stock Traders Daily
HPV positive oropharyngeal cancer strategy accelerates with new CRB-701 data at Corbus Pharmaceuticals Holdings, Inc. - Traders Union
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 2000 Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Benchmark - marketscreener.com
CRBP Q1 2026 Earnings: EPS Beats Estimates Amid Pipeline ProgressAnalyst Consensus Shift - dars.gov.et
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 3000E Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Completeness Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 3000 Index - marketscreener.com
CRBP Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Price to sales forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. – BOATS:CRBP - TradingView
Corbus Pharmaceuticals (CRBP) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
CRBP Maintained by Mizuho -- Price Target Lowered to $34 - GuruFocus
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):